Suppr超能文献

肾衰竭和骨吸收增加在骨髓瘤高钙血症中的相对重要性。

Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis.

作者信息

Heyburn P J, Child J A, Peacock M

出版信息

J Clin Pathol. 1981 Jan;34(1):54-7. doi: 10.1136/jcp.34.1.54.

Abstract

In order to define the relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis 22 untreated patients were studied, of whom 12 were hypercalcaemic. Most patients had malabsorption of radiocalcium from the gastrointestinal tract and evidence of increased bone resorption as assessed by fasting urinary hydroxyproline/creatinine ratio. The mean OHPr/Cr ratio, however, was similar in patients with and without hypercalcaemia. Renal failure and Bence Jones proteinuria occurred more frequently in the hypercalcaemic patients. In four patients with hypercalcaemia there was an increase in OHPr/Cr after saline infusion accompanied by an improvement in renal function and hypercalcaemia. Mithramycin given to the same patients further reduced hypercalcaemia, presumably by inhibiting bone resorption. It was concluded that the hypercalcaemia of myelomatosis is due to the combination of renal failure and increased bone resorption, but that the OHPr/Cr ratio in the untreated state is a poor indicator of the degree of bone resorption in hypercalcaemic patients.

摘要

为了确定肾衰竭和骨吸收增加在骨髓瘤高钙血症中的相对重要性,对22例未经治疗的患者进行了研究,其中12例存在高钙血症。大多数患者存在胃肠道放射性钙吸收不良,且通过空腹尿羟脯氨酸/肌酐比值评估有骨吸收增加的证据。然而,有高钙血症和无高钙血症患者的平均OHPr/Cr比值相似。高钙血症患者肾衰竭和本周蛋白尿更常见。4例高钙血症患者在输注生理盐水后OHPr/Cr升高,同时肾功能和高钙血症有所改善。给予相同患者光辉霉素后高钙血症进一步降低,推测是通过抑制骨吸收实现的。得出的结论是,骨髓瘤高钙血症是肾衰竭和骨吸收增加共同作用的结果,但在未经治疗的状态下,OHPr/Cr比值并不能很好地反映高钙血症患者的骨吸收程度。

相似文献

2
Treatment of osteolytic myelomatosis with mithramycin.
Lancet. 1975 Mar 29;1(7909):719-22. doi: 10.1016/s0140-6736(75)91631-1.
7
[Treatment of hypercalcemia with mithramycin].
Rev Rhum Mal Osteoartic. 1975 Feb;42(2):93-6.
8
Prognostic factors in myelomatosis.骨髓瘤的预后因素。
Br Med J. 1971 May 8;2(5757):327-8. doi: 10.1136/bmj.2.5757.327-b.
9
The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma.
Br J Haematol. 1983 May;54(1):121-32. doi: 10.1111/j.1365-2141.1983.tb02074.x.
10
[Severe hypercalcemia after rhabdomyolysis and acute renal failure].
Ann Fr Anesth Reanim. 1991;10(5):482-5. doi: 10.1016/s0750-7658(05)80855-x.

本文引用的文献

4
Treatment of Paget's disease of bone with mithramycin.
Br Med J. 1971 Feb 20;1(5746):421-3. doi: 10.1136/bmj.1.5746.421.
5
Serum calcium in a geriatric inpatient population.
Age Ageing. 1973 Aug;2(3):157-62. doi: 10.1093/ageing/2.3.157.
7
Paraproteins, benign or malignant?副蛋白,良性还是恶性?
Br Med J. 1967 Sep 16;3(5567):699-704. doi: 10.1136/bmj.3.5567.699.
8
Prognostic factors in multiple myeloma.多发性骨髓瘤的预后因素
Cancer. 1975 Oct;36(4):1192-201. doi: 10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i.
9
Mechanism of the hypocalcemic effect of mithramycin.
J Clin Endocrinol Metab. 1979 Feb;48(2):341-4. doi: 10.1210/jcem-48-2-341.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验